Clinical Trial Detail

NCT ID NCT03616574
Title First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Holy Stone Healthcare Co., Ltd
Indications

colorectal cancer

Advanced Solid Tumor

Therapies

CA102N

CA102N + trifluridine/tipiracil hydrochloride

Age Groups: adult senior

No variant requirements are available.